Santhera reported a 70% year-on-year revenue jump to CHF 24 million for the first half of 2025 as Agamree (vamorolone) continued to scale globally, with trailing four-quarter sales across Santhera and partners surpassing USD 100 million. That milestone triggered a USD 25 million payment booked in cost of sales, helping drive a CHF 35.4 million operating loss despite a 76% increase in product sales to CHF 11.6 million and CHF 5.4 million in royalties. Cash stood at CHF 18.4 million at mid-year, subsequently bolstered by roughly CHF 20 million of growth capital in September via a royalty monetization with R-bridge and an upsized convertible from Highbridge. Santhera now expects 2025 revenue to exceed prior guidance and maintains cash-flow break-even for mid-2026, while advancing new distribution agreements across the GCC, India, and Türkiye.
The strategic question is whether Santhera can convert rapid early uptake into durable, reimbursed revenue in Europe while relying on financing tools that trade future royalty income for near-term liquidity. Agamree is behaving like a rare-disease commercial winner—fast share capture, strong US partner performance, and expanding geographies—but the company’s capital stack and milestone obligations mean execution on pricing, access, and inventory is just as important as clinical differentiation.
This matters now because steroid management remains the backbone of Duchenne care even as novel modalities progress. Clinician adoption in Germany and Austria—approximately 40% and more than 50% of corticosteroid-using patients treated, respectively—signals willingness to switch from legacy corticosteroids toward a dissociative steroid positioned for improved tolerability. UK availability following favorable guidance, along with rising use in older patients and growing combination therapy with givinostat, points to broadening clinical integration. For payers, the upcoming Guardian long-term data and real-world evidence from early-launch markets will be pivotal to justify premium positioning and inform utilization management, especially in Spain, Italy, the Nordics, and France, where HTA outcomes will set the pace of 2026 growth. Patients may benefit from fewer steroid-associated adverse effects, while health systems will scrutinize adherence, functional outcomes, and budget impact as treatment duration lengthens.
Commercially, Catalyst’s US trajectory toward USD 100–110 million in 2025 underpins the franchise’s potential and could unlock an additional USD 12.5 million milestone to Santhera. Yet the September royalty deal routes up to 100% of North America and China royalties to R-bridge until capped, prioritizing launch acceleration and inventory over near-term royalty cash. That amplifies the importance of Santhera’s direct-market performance in Europe and its distributor-led territories. In China, a non-reimbursed rollout with more than 250 patients demonstrates demand formation, but sustained growth will depend on reimbursement pathways and patient support programs.
The playbook reflects broader 2025 rare disease trends: partner-heavy models in the US and China, lean European builds, early access to seed demand, and royalty monetizations as a bridge to profitability. As gene therapies evolve but still rely on background disease management, therapies that mitigate steroid toxicity can gain share now and potentially coexist with future standards.
The near-term verdict will hinge on two levers: the strength of Guardian’s long-term outcomes and the outcome of HTA negotiations across major EU markets. If Santhera lands favorable access and sustains switching across age cohorts and in combinations, it edges from a single-asset story toward a durable rare-disease platform. If European reimbursement lags or China growth stalls without coverage, the key question becomes how long commercial momentum can outrun the cost of capital and monetized royalties.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
